Interleukin-2 receptors: biology and therapeutic potentials

Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.

Leukemia·2014

Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.

Gene therapy·2014

Intrathecal effects of daclizumab treatment of multiple sclerosis.

Neurology·2011

Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens.

Nature·2011

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.

Oncogene·2007

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

Leukemia research·2005

Oral contraceptives: an update.

Hospital practice (Office ed.)·1995

Progress in the immunogenetics of rheumatoid arthritis.

Hospital practice (Office ed.)·1995

Defusing status epilepticus.

Hospital practice (Office ed.)·1995

Advances in Wegener's granulomatosis.

Hospital practice (Office ed.)·1995

Individualizing drug therapy for the hypertensive patient.

Hospital practice (Office ed.)·1995

Penicillin for streptococcal pharyngitis: has anything changed?

Hospital practice (Office ed.)·1995

Increased anergic B cells and decreased antibody-secreting cells during romiplostim treatment in patients with immune thrombocytopenia.

British journal of haematology·2026

Passive Transfer of Hepatitis B Core Antibody Following Intravenous Ig Administration: Clinical Implications and Considerations.

ACR open rheumatology·2026

Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study.

BMC neurology·2026

iPSC-derived neurospheres: A cellular platform for Tau and Alzheimer's disease immunotherapy.

Advances in immunology·2026

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Lancet (London, England)·2026

Related Experiment Videos

Interleukin-2 receptors: biology and therapeutic potentials

Related Concept Videos

Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.

Vaccination with tumor cells expressing IL-15 and IL-15Rα inhibits murine breast and prostate cancer.

Intrathecal effects of daclizumab treatment of multiple sclerosis.

Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens.

Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.

Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing.

Oral contraceptives: an update.

Progress in the immunogenetics of rheumatoid arthritis.

Defusing status epilepticus.

Advances in Wegener's granulomatosis.

Individualizing drug therapy for the hypertensive patient.

Penicillin for streptococcal pharyngitis: has anything changed?

Increased anergic B cells and decreased antibody-secreting cells during romiplostim treatment in patients with immune thrombocytopenia.

Passive Transfer of Hepatitis B Core Antibody Following Intravenous Ig Administration: Clinical Implications and Considerations.

Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study.

iPSC-derived neurospheres: A cellular platform for Tau and Alzheimer's disease immunotherapy.

Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.

Related Experiment Videos

Interleukin-2 receptors: biology and therapeutic potentials

Related Concept Videos

Related Articles